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Berberine (BBR) is an organic small molecule isolated from various plants that have been used in traditional Chinese medicine. 
Isolation of this compound was its induction into modern medicine, and its usefulness became quickly apparent as seen in its 
ability to combat bacterial diarrhea, type 2 diabetes, hypercholesterolemia, inflammation, heart diseases, and more. However, 
BBR’s effects on neurodegenerative diseases remained relatively unexplored until its ability to stunt Alzheimer’s disease (AD) 
progression was characterized. In this review, we will delve into the multi-faceted defensive capabilities and bio-molecular 
pathways of BBR against AD, Parkinson’s disease (PD), and trauma-induced neurodegeneration. The multiple effects of BBR, 
some of which enhance neuro-protective factors/pathways and others counteract targets that induce neurodegeneration, suggest 
that there are many more branches to the diverse capabilities of BBR that have yet to be uncovered. The promising results seen 
provide a convincing and substantial basis to support further scientific exploration and development of the therapeutic potential 
of BBR against neurodegenerative diseases. 
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Berberine (BBR) is an organic compound isolated from 
various herbs such as Coptis chinensis, Berberis vulgaris, 
Hydrastis Canadensis, Phellodendron amurense. For dec-
ades, Chinese medicine has used the plants and their ex-
tracts to treat diarrhea with no observable negative 
side-effects or toxicity in patients [13]. Modern advances 
in research, however, allowed us to discover BBR as the 
active compound and to synthesize it. As a result, BBR was 
found to be a small molecule with a molecular weight of 
only 371.8 Da [3] (Figure 1).  
BBR has been used clinically to treat bacterial diarrhea, 
hypercholesterolemia, type 2 diabetes, cardiac disease, can-
cer, and more [314]. Although studies in rodents have 
shown that BBR can cross the blood brain barrier with posi- 
 
Figure 1  Molecular structure of berberine. 
tive effects on brain function, the mechanism remains un-
clear [15]. This factor points to the possibility that BBR 
may have pronounced effects on the brain and central nerv-
ous system. Additionally, in animal trials, BBR has shown 
itself to have positive effects on Alzheimer’s and Parkin-
 Jiang WX, et al.   Sci China Life Sci   June (2015) Vol.58 No.6 565 
son’s models [16,17]. Although we possess only a nascent 
understanding of BBR’s effects and mechanisms on the 
brain and nervous system, its protective effects on Alz-
heimer’s and Parkinson’s cellular and animal models and its 
uncanny ability to act with robust diversity, begin to shed 
light on BBR’s abilities to positively effect the outcome in 
diseases of the central nervous system. 
According to the Center of Disease Control in the United 
States, an estimated 5 million people suffer from Alz-
heimer’s disease (AD) [18]. AD is a late-onset disease, typ-
ically presenting after age 60, and is characterized by 
memory loss and handicapped daily functions. To date, the 
exact cause of AD has not been pinpointed, with scientists 
currently believing the disease to arise from multiple con-
tributing factors including genetic and environmental influ-
ences. However, pathological evidence always rests with 
beta-amyloid plaque build-up in the brain [19]. Despite the 
prevalence and severity of AD, its complexity has left mod-
ern science without answer, but in dire need of treatment 
options. 
Parkinson’s disease (PD) is another common form of 
neurological disease that presents classically with resting 
tremor, rigidity, bradykinesia, postural instability and often-
times, senile dementia [20]. PD is highly prominent espe-
cially in western European populations in which the preva-
lence rate is estimated at 160 per 100,000 and as high as 4% 
amongst persons over the age of 80 [20]. Although the di-
rect pathological cause of PD has been stemmed to protein 
aggregations (called Lewy bodies) and loss of dopaminergic 
cells in the substantia nigra, the etiology behind PD is be-
lieved to be highly diverse [20,21] and the exact pathogenic 
mechanism is still unclear. Although current treatments for 
PD include dopamine agonists and monoamine oxidase B 
(MAO-B) inhibitors to reduce breakdown of dopamine, they 
are symptom-targeted and also produce serious side-effects 
[22]. To date, a cure or treatment without severe side-effects 
for PD has eluded modern science. 
1  The therapeutic effect of BBR on AD 
Although no single underlying cause has been established 
for beta-amyloid plagues-associated AD, metabolic imbal-
ances have been found in AD patients and are likely to con-
tribute to the symptoms of the disease. Due to its mul-
ti-faceted nature, BBR has been shown to address several of 
those imbalances in a positive way. These activities include 
cholesterol reduction, ERK pathway activation, inhibition of 
MAO-B activity, defense against damage from reactive ox-
ygen species (ROS), inhibition of acetylcholinesterase 
(AChE), butyrylcholinesterase (BChE) activity, and be-
ta-secretase, and reduction in the amyloid-beta genesis 
[3,2326]. This has led to an overall reduction in amyloid 
plaque aggregation and reduction in phenotypic pathology 
of AD in the mouse model [27]. 
In 2009, Jung et al. [24] ran a number of inhibitory as-
says to determine the anti-AD effects of several protober-
berine alkaloids. The IC50 (50% inhibitory concentration) 
was determined for each of the six compounds in their abil-
ity to stunt an AD-related activity. The inhibitory assays 
included β-site amyloid precursor protein cleaving enzyme 
1 (BACE1), AChE, BChE, and reactive oxygen species 
(ROS). In addition to total ROS, peroxynitrite (ONOO−) 
scavenging was given particular attention due to its strong 
role in amyloid B formation. Through these assays, Jung et 
al. [24] found that although BBR was ineffective at inhibi-
tion of BACE1 and total ROS, the compound showed 
promising results against AChE, BChE, and ONOO (re-
quiring 0.44, 3.44, and 23.06 µmol L1 respectively to reach 
IC50 of a 100 µmol L1 target solution). 
In 2013, Panahi et al. [25] showed that with 50 mg kg1 
oral BBR taken daily, rabbits with chemically-induced 
AD-like symptoms showed improvement as compared to 
the untreated group. Although weight loss was only moder-
ately abated, survival was significantly improved. Interest-
ingly, the results showed significant inhibition of BACE1 in 
the treatment group, which stand in contrast to the prior 
findings of Jung et al. [24]. 
Asai et al. [26] also discovered that 10 µmol L1 BBR 
could reduce amyloid B levels to 30% of the untreated 
amount in vitro. Furthermore, through Western-blotting of 
the different components of amyloid precursor protein 
(APP), they discovered that the mechanism behind the re-
duction was the result of APP pathway modulation towards 
a non-amyloid metabolite, as opposed to direct destruction 
of the protein itself or of its precursor [26]. 
Using a transgenic AD model mouse strain (CRN8D), 
Durairajan et al. [27] tested the effects of BBR on neuro-
logical impairment. The group found that BBR significantly 
reduced amyloid B plaque aggregation, leading to ameliora-
tion of mental and neuronal impairment in the treated group 
as compared to untreated transgenic control. Results also 
showed that these effects were achieved through inhibition 
of APP phosphorylation via suppression of glycogen syn-
thase kinase (GSK) 3 activation [27]. In addition, the group 
found that treatment with a lower dosage (25 mg kg1) often 
showed preferential results as compared to treatment with a 
higher dosage (100 mg kg1) [27].    
All these studies present consistent information of BBR’s 
effects against the various components of AD pathogenesis 
and its treatment results as manifested in the amelioration of 
AD pathology, presentation, and progression. Furthermore, 
the dosage study done by Durairajan et al. [27] suggests that 
to further develop the therapeutic capabilities of BBR against 
AD, biochemical approaches must be elicited, as increases in 
concentration can be counter-productive in treatment. 
2  The therapeutic effect of BBR on PD 
Although the pathology of Parkinson’s Disease (PD) has  
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been pinned to the formation of Lewy body protein aggre-
gates and loss of dopaminergic neurons in the brain, the 
causes that lead up to the pathology are largely unknown. 
Due to our lack of understanding of the true cause of this 
disease, effective treatment strategies remain to be devel-
oped. Thus, current therapies against PD are limited to ame-
lioration of its symptoms, the main focus of which is 
stemmed around prevention or retardation of further dopa-
minergic neuronal loss. There has been substantially less 
research done on the therapeutic potential of BBR against 
PD than there has been against AD; mixed results and lack 
of clear success could be the main reasons. However, there 
are at least two documented effects that merit BBR or at 
least some derivative or metabolite in consideration for con-
tinued studies to further address the possibility of its use as 
an anti-PD agent.  
In 2014, Kim et al. [28] used a chemically-induced 
mouse model of PD to test the neuro-protective effect of 
BBR. According to their data, at 50 mg kg1, BBR signifi-
cantly prevented both memory and balance loss in those PD 
mice as compared to their untreated counterparts. They 
found that there was corresponding lack of dopaminergic 
neuronal loss in the substantia nigra and decreases apoptosis 
in the hippocampus of the treated group as compared with 
the untreated control [28]. This recent study showed a very 
promising outlook for BBR for consideration as a select 
compound for treatment against PD. 
However, the results of Kim et al. stand in stark contrast 
to the findings of the Lee group in South Korea, which pub-
lished two accounts [29,30] of the neurotoxic effects of 
BBR when used to treat chemically-induced rat models of 
PD. In these studies, first, a PC12 cell model of PD showed 
that when treated with BBR, dopaminergic loss was elevat-
ed as compared to the untreated controls [29]. Treatment of 
a PD rat model with BBR (both at 5 and 15 mg kg1) ag-
gravated depletion of dopamine and norepinephrine as well 
as degeneration of tyrosine hydroxylase-immunopositive 
cells in vivo [30]. It is important to note that the differences 
in findings between the Lee group and Kim et al. could pos-
sibly be partially attributed to their differences in animal 
models (mouse vs. rat) and the species-dependent rates of 
BBR metabolism. 
As MAO-A and MAO-B are both natural dopamine- de-
grading agents, their inhibition has always been therapeutic 
strategy against PD. However, due to the toxic side-effects 
of MAO inhibitors, this route has usually been reserved as 
the final effort in a patient’s treatment against advancing PD. 
Castillo et al. [31] used direct LED fluorescence to detect 
changes in MAO-B levels in hopes of using the method as a 
way to confirm the successes of various MAO-B inhibiting 
agents in PD treatment. Although it was previously known 
that BBR could inhibit MAO activity (with an IC50 of 126 
µmol L1 for MAO-A and 98.4 µmol L1 for MAO-B), the 
results of this study put into perspective the usability of 
BBR as a MAO-inhibitor for PD treatment [23,31,32]. 
Compared to other MAO inhibitors that can often be highly 
toxic, BBR is highly preferable for its safety. 
Bae et al. [33] discovered from in vitro studies using the 
human-derived SH-SY5Y cells as an in vitro model of do-
paminergic neurons that BBR prevented cell death by pro-
tecting against ROS damage. The mechanism relied on ac-
tivation of heme oxygenase-1 and inhibition of caspase-3 
activation to parry neuronal apoptosis [33].  
Taken together, while these results do show the possibili-
ties of BBR as a therapeutic agent against PD, they also 
suggest proceeding with caution, as slight species-depend- 
ent differences in BBR metabolism could account for dif-
ferent efficacy or even effect of BBR.  
3  General neuroprotective effects of BBR 
BBR has also shown broadened neuroprotective effects. 
General oxidative damage to neurons and neurodegenera-
tion plays an important role in a wide range of neurological 
disorders. To achieve its neuroprotective effects, BBR has 
been reported to activate nuclear factor-like 2 (Nrf2), aid in 
phosphorylation of Protein Kinase B (Akt), and cAMP re-
sponse element binding protein (CREB), down-regulate 
nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-B), and enhance phosphoinositide 3-kinase 
(PI3K) expression via (P55y subunit) increasing promoter 
activity [3444]. 
Using mouse neuroblastoma cell lines, Hsu et al. [34] 
determined the in vitro neuroprotective effects of BBR. 
They found that in addition to the known anti-oxidative 
pathways, BBR was also capable of activating Nrf2, an an-
ti-oxidant factor. Furthermore, they also found evidence that 
BBR stymied neuronal cell death by bolstering B-cell lym-
phoma-2 (Bcl-2), an antagonist of apoptosis. 
In addition, Zhang et al. [35] used a rat stroke model to 
test the abilities of BBR to protect against stroke. They 
found BBR to be neuroprotective in the acute phase of the 
stroke when administered immediately after insult. They 
also traced the BBR’s ability to up-regulate phosphorylation 
of neuroprotective factors: Akt, and CREB. BBR was also 
found to down-regulate the inflammatory response factor, 
NF-B, to suppress inflammation in the area [35]. Interest-
ingly, they also discovered that BBR can affect the permea-
bility of the blood-brain barrier by up-regulating the integral 
membrane protein, claudin-5 [35].     
In 2011, Hu et al. [36] found that in a mouse model with 
surgically induced stroke, BBR presented a unique way of 
bypassing a self-insulting down-regulation of the cell 
growth/proliferation factor, PI3K. In their model, BBR 
could target the P55y subunit of PI3K and enhance its pro-
moter activity while side-stepping its natural antagonists, 
Ly294002 and Akti-1/2, which is also an Akt inhibitor [36]. 
This resulted in significantly enhanced reperfusion to the 
damaged areas as compared to the untreated controls [36]. 
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Interestingly, this group chose caudal intravenous admin-
istration of BBR between 0.002 and 0.2 mg kg1 as opposed 
to the more economic, safer, and much more commonly 
used oral gavage route.   
4  Effects of BBR on the common pathways in 
neurodegeneration 
The multifaceted abilities of BBR to act against several 
neurodegenerative conditions or afflictions suggest that it 
may act on the shared pathways of neurodegeneration in 
these diseases. MAO-B inhibition has been implicated to 
have positive effects against both Alzheimer’s and Parkin-
son’s patients [45,46]. A possible reason could be that the 
MAO-B-mediated dopamine metabolism pathway leads to 
H2O2 generation and as MAO-B activity is elevated in AD 
and PD, the excess H2O2 can cause oxidative stress and 
damage [47]. Damage, as well as proapoptotic stimulation 
from reactive oxygen species (ROS) has also been impli-
cated in a wide array of neurodegenerative afflictions [48,49] 
and the ability of BBR to counteract ROS certainly serves to 
uphold its ability to affect a diverse group of ailments in 
which neurodegeneration is a major factor. Furthermore, 
BBR’s inhibitory effects on AChE could lead to effects on a 
great number of neurodegenerative diseases as AChE has 
exhibited apoptotic induction, in addition to its general role 
as antagonist to acetylcholine [50]. Because of this, AChE 
inhibition is already in use as a therapeutic approach to cur-
tailing neurodegeneration [51]. General neuro-protective 
factors that BBR can enhance or up-regulate include Nrf2, 
GLP-1 and others. Nrf2 has shown neuroprotection through 
a pathway that defends against ROS damage [52,53]. GLP-1 
up-regulation and receptor stimulation has exhibited neu-
ro-protective effects to preserve dopaminergic neurons, 
which have applications in stroke, AD, PD, Huntington’s 
disease (HD) and more [5456]. Additionally, BBR’s abil-
ity to phosphorylate AKT and activate the PI3K-AKT sig-
naling pathway results in the ability to resist apoptosis via 
inhibition of caspases and cytochrome C [5759]. CREB is 
another important protein, the phosphorylation of which can 
be up-regulated by BBR. Research has shown pCREB to be 
an essential part of neurons that survive insult, and knock-
ing it down could cause neurodegeneration in the brain 
[60,61]. Due to these common pathways that result in neu-
rodegeneration, BBR is able to affect a great number of 
disorders in which neurodegeneration is key (Figure 2). 
To summarize, BBR has exhibited promising neuropro-
tective properties through a multitude of known bio-    
molecular pathways and undoubtedly a vast number of un-
known ones to not only defend against neuronal damage 
and loss but also to aid in reperfusion of previously dam-
aged tissue. Furthermore, due to the multi-faceted nature of  
 
Figure 2 (color online)  BBR interacts with many pathways that are affil-
iated with neurodegeneration or neuroprotection. 
BBR, there are sure to be more that await discovery, some 
of which could hold the keys to some of the stubborn neu-
rodegenerative diseases that need effective treatments.  
5  Conclusion 
BBR has shown great therapeutic potential against neuro-
degenerative diseases including AD and PD as well as 
stroke. Its ability to effectively cross the blood-brain barrier 
as well as its small size, which allows for the uncanny abil-
ity to act on a number of molecular targets, is a pillar of its 
merit as an anti-neurodegenerative agent. Because of the 
extensive range of effects, BBR is likely to treat diseases in 
a positive way by correcting multiple deficiencies and tack-
ling the problem from multiple angles simultaneously. One 
possibility is that BBR may help clear toxic products or 
misfolded proteins to achieve multi-faceted benefits in re-
ducing cellular toxicity. However, BBR is unlikely to have 
a very strong effect on any single one of these aspects, 
which may prevent harmful levels of imbalance and side 
effects. These facts coupled with its overall favorable ef-
fects on brain function suggest a potential myriad of other 
undiscovered applications on neurodegenerative diseases. 
The other pillar is its safety, as there have been no docu-
mented serious toxic effects even in high doses given orally. 
Because of this crucial feature, it has been safely clinically 
used in China for decades even for long-term treatment as 
an over-the-counter medication and is widely available in 
health stores in the US that require no prescription to pur-
case. Therefore, upon even mild-moderate success on ani-
mal models, BBR could quickly advance through clinical 
trials (for specific ailments) rather than taking the usual 
several long steps before being deemed safe. On a final note, 
the therapeutic potential of BBR shows promising potential 
and merits great interest and research investment for future 
development and exploration into the possibilities of this 
multi-faceted, non-toxic botanic compound.  
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